BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Borsa Italiana 12:34:56 2024-06-19 EDT | ||
| 32.4 EUR | 0.00% |
|
| Current month | +25.61% | ||
| 1 month | +52.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 32.4 | 0.00% |
| 24-06-18 | 32.4 | +1.50% |
| 24-06-17 | 31.92 | +2.08% |
| 24-06-14 | 31.27 | -1.42% |
| 24-06-13 | 31.72 | +4.79% |
Real-time Borsa Italiana
Last update June 19, 2024 at 12:34 pm
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S33390 | |
| ISIN | DE000SU58T46 |
| Date issued | 2023-12-28 |
| Strike | 547.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.92 € |
|---|---|
| Lowest since issue | 5.33 € |
| Spread | 0.2 € |
| Spread % | 0.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- S33390 Certificat
